These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8267408)

  • 1. Current perspectives: iron management during therapy with recombinant human erythropoietin.
    York S
    ANNA J; 1993 Dec; 20(6):645-50; quiz 651-2. PubMed ID: 8267408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron management during treatment with recombinant human erythropoietin in chronic renal failure.
    Watson A
    J Clin Pharmacol; 1993 Dec; 33(12):1134-8. PubMed ID: 8126248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron management during recombinant human erythropoietin therapy.
    Van Wyck DB
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
    Van Wyck DB
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case management of the anemic patient: epoetin alfa--focus on iron supplementation.
    Kirlin LF
    ANNA J; 1993 Dec; 20(6):678-81. PubMed ID: 8267412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia of renal failure. Use of erythropoietin.
    Humphries JE
    Med Clin North Am; 1992 May; 76(3):711-25. PubMed ID: 1578966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of iron in erythropoiesis in the absence and presence of erythropoietin therapy.
    Goodnough LT
    Nephrol Dial Transplant; 2002; 17 Suppl 5():14-8. PubMed ID: 12091601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Individual differences in the efficacy of Recormon in patients with terminal kidney failure. The role of iron deficiency].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kondakhchan MA; Rogov VA; Trofimova EI
    Ter Arkh; 1993; 65(6):45-8. PubMed ID: 8378849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of rHuEPO resistance in CRF patients: a clinical protocol at Winthrop-University Hospital.
    Trenkle JA
    ANNA J; 1998 Jun; 25(3):333-8, 344. PubMed ID: 9801489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Iron stores in patients with chronic kidney failure treated with recombinant human erythropoietin].
    Cermák J; Gregora E; Lachmanová J; Brabec V
    Vnitr Lek; 1994 Mar; 40(3):174-8. PubMed ID: 8184571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of iron in optimizing responses of anemic cancer patients to erythropoietin.
    Glaspy J; Cavill I
    Oncology (Williston Park); 1999 Apr; 13(4):461-73; discussion 477-8, 483-8. PubMed ID: 10234700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of renal anemia.
    Peco-Antic A
    Turk J Pediatr; 2005; 47 Suppl():19-27. PubMed ID: 15884663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia.
    Garrido P; Ribeiro S; Fernandes J; Vala H; Rocha-Pereira P; Bronze-da-Rocha E; Belo L; Costa E; Santos-Silva A; Reis F
    Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive therapy in anaemia management.
    Hörl WH
    Nephrol Dial Transplant; 2002; 17 Suppl 5():56-9. PubMed ID: 12091609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy.
    Eschbach JW; Adamson JW
    Kidney Int Suppl; 1999 Mar; 69():S35-43. PubMed ID: 10084284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment.
    Ramírez B; Flores A; Pérez F; Córdoba C; García L; Vázquez G
    Transplant Proc; 1991 Apr; 23(2):1833-4. PubMed ID: 2053170
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythropoietin and iron: the role of ascorbic acid.
    Tarng DC; Huang TP; Wei YH
    Nephrol Dial Transplant; 2001; 16 Suppl 5():35-9. PubMed ID: 11509682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical approach to initiation of recombinant human erythropoietin therapy and prevention and management of adverse effects.
    Abraham PA
    Am J Nephrol; 1990; 10 Suppl 2():7-14. PubMed ID: 2260619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.